Novartis AG
Substituted 5-cyanoindole compounds and uses thereof

Last updated:

Abstract:

A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for the treatment of lysine (K)-specific demethylase 1A (LSD1)-mediated diseases or disorders: ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.5 are as defined herein.

Status:
Grant
Type:

Utility

Filling date:

19 Jun 2018

Issue date:

31 Mar 2020